{
  "items": "37",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "(IMTX) Movement as an Input in Quant Signal Sets",
      "url": "https://news.stocktradersdaily.com/news_release/89/IMTX_Movement_as_an_Input_in_Quant_Signal_Sets_122725070202_1766836922.html",
      "time_published": "20251227T070200",
      "authors": [
        "Juan A",
        "Thomas H. Kee Jr."
      ],
      "summary": "This article details a quantitative analysis of Immatics N.v. (NASDAQ: IMTX) using AI models, identifying a near-term strong sentiment transitioning to a long-term positive bias. It outlines distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones based on a 70.0:1 risk-reward setup. The analysis also provides multi-timeframe signal insights, including support and resistance levels.",
      "banner_image": "https://news.stocktradersdaily.com/media/695147_IMTX_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.932225"
        },
        {
          "topic": "finance",
          "relevance_score": "0.823269"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.730690"
        }
      ],
      "overall_sentiment_score": 0.402839,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.404103",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "How Immatics\u2019 US$125 Million Follow-on Equity Raise At Immatics (IMTX) Has Changed Its Investment Story",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imtx/immatics/news/how-immatics-us125-million-follow-on-equity-raise-at-immatic",
      "time_published": "20251218T071022",
      "authors": [
        "Sasha Jovanovic"
      ],
      "summary": "Immatics N.V. recently completed a US$125 million follow-on equity offering, selling 12.5 million shares at US$10 each. This capital raise strengthens its balance sheet and potentially extends the runway for its TCR-based immunotherapy platform's clinical trials, acting as a short-term catalyst while also diluting existing shareholders. The financing's impact on long-term prospects depends on how efficiently the fresh capital is deployed, especially given increased cash-burn and ongoing unprofitability.",
      "banner_image": "https://images.simplywall.st/company/7996d409-6967-4c33-9f0a-b9c11b08e623/chart/quote-price",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.802187"
        },
        {
          "topic": "finance",
          "relevance_score": "0.747726"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.937415"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.647287"
        },
        {
          "topic": "technology",
          "relevance_score": "0.602765"
        }
      ],
      "overall_sentiment_score": 0.042998,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.334856",
          "ticker_sentiment_score": "0.031135",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "How Immatics\u2019 US$125 Million Follow-on Equity Raise At Immatics (IMTX) Has Changed Its Investment Story",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imtx/immatics/news/how-immatics-us125-million-follow-on-equity-raise-at-immatic/amp",
      "time_published": "20251217T130905",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Immatics N.V. recently completed a US$125 million follow-on equity offering, raising capital at US$10 per share. This significant fundraising strengthens the company's balance sheet after substantial net losses, potentially extending the runway for pipeline trials and partnership work. However, the issuance of new shares at a discount dilutes existing holders and highlights the ongoing need for funding.",
      "banner_image": "NULL",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.935490"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.805735"
        }
      ],
      "overall_sentiment_score": 0.003754,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.339836",
          "ticker_sentiment_score": "0.017862",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics completes $116.5 million share offering to boost R&D",
      "url": "http://www.msn.com/en-us/money/savingandinvesting/immatics-completes-116-5-million-share-offering-to-boost-r-d/ar-AA1RXZl0?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
      "time_published": "20251217T080905",
      "authors": [],
      "summary": "Immatics has successfully completed a $116.5 million share offering, significantly strengthening its financial position. The capital raised will primarily be allocated to advancing the company's research and development initiatives, particularly its clinical programs. This move is expected to accelerate the development of its innovative cell and gene therapies.",
      "banner_image": null,
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.832005"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.713421"
        }
      ],
      "overall_sentiment_score": 0.438148,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.431791",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "(IMTX) Volatility Zones as Tactical Triggers",
      "url": "https://news.stocktradersdaily.com/news_release/20/IMTX_Volatility_Zones_as_Tactical_Triggers_121625054401_1765881841.html",
      "time_published": "20251216T054400",
      "authors": [
        "Jeff W."
      ],
      "summary": "This article provides a stock analysis for Immatics N.v. (NASDAQ: IMTX), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details three AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014along with multi-timeframe signal analysis, including support and resistance levels. The analysis also emphasizes an exceptional risk-reward setup targeting a 23.8% gain against a minimal 0.3% risk.",
      "banner_image": "https://news.stocktradersdaily.com/media/687188_IMTX_graph.jpg",
      "source": "Stock Traders Daily",
      "category_within_source": "General",
      "source_domain": "Stock Traders Daily",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.906172"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.741823"
        }
      ],
      "overall_sentiment_score": 0.057405,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.091211",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics N.V. (NASDAQ:IMTX) Receives Consensus Recommendation of \"Moderate Buy\" from Analysts",
      "url": "https://www.marketbeat.com/instant-alerts/immatics-nv-nasdaqimtx-receives-consensus-recommendation-of-moderate-buy-from-analysts-2025-12-14/",
      "time_published": "20251214T090919",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Immatics N.V. (NASDAQ:IMTX) has been given a consensus \"Moderate Buy\" rating by eight analysts, with an average 12-month price target of $18.80. The company's shares are currently trading around $10.04, and its market capitalization is $1.22 billion. Institutional investors own a significant portion of the stock, and several firms have recently increased their positions.",
      "banner_image": "https://www.marketbeat.com/logos/immatics-logo-1200x675.png?v=20240509152140",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.914615"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.845620"
        },
        {
          "topic": "finance",
          "relevance_score": "0.726693"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.628120"
        }
      ],
      "overall_sentiment_score": 0.161502,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.213674",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.592308",
          "ticker_sentiment_score": "0.167304",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.593069",
          "ticker_sentiment_score": "0.195551",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.587570",
          "ticker_sentiment_score": "0.196121",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.575663",
          "ticker_sentiment_score": "0.156529",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Immatics Announces Promising Phase 1a Dose Escalation Results for IMA203CD8, a Second-Generation PRAME Cell Therapy for Advanced Solid Tumors",
      "url": "https://www.quiverquant.com/news/Immatics+Announces+Promising+Phase+1a+Dose+Escalation+Results+for+IMA203CD8%2C+a+Second-Generation+PRAME+Cell+Therapy+for+Advanced+Solid+Tumors",
      "time_published": "20251211T121400",
      "authors": [],
      "summary": "Immatics N.V. has reported encouraging preliminary results from its Phase 1a dose escalation trial for IMA203CD8, a second-generation PRAME cell therapy for advanced solid tumors. The treatment demonstrated manageable tolerability across all dose levels and promising anti-tumor activity, especially in ovarian carcinoma, with a confirmed objective response rate of 36% and a disease control rate of 84% in heavily pre-treated patients. The company is on track to determine the recommended Phase 2 dose by 2026, highlighting IMA203CD8's potential for tumor-agnostic application beyond melanoma.",
      "banner_image": "https://www.quiverquant.com/images/imtx_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.490882,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.488260",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Immatics (NASDAQ: IMTX) reports 46% ORR for IMA203CD8 in Phase 1a PRAME solid tumors",
      "url": "https://www.stocktitan.net/news/IMTX/immatics-presents-ima203cd8-prame-cell-therapy-data-from-ongoing-tszj1k0xafvk.html",
      "time_published": "20251211T120929",
      "authors": [
        "NULL"
      ],
      "summary": "Immatics (NASDAQ: IMTX) announced updated Phase 1a dose-escalation data for its second-generation PRAME cell therapy IMA203CD8, showing a 46% objective response rate (ORR) and 36% confirmed ORR in PRAME-positive solid tumors. The treatment demonstrated manageable tolerability and durable responses, with particular promise in ovarian carcinoma. Immatics plans to determine the recommended Phase 2 dose (RP2D) in 2026 as dose escalation continues.",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/754fba1f-531a-483b-a574-a027f4add35e/image1.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.843697"
        }
      ],
      "overall_sentiment_score": 0.140865,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.985604",
          "ticker_sentiment_score": "0.339627",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.550489",
          "ticker_sentiment_score": "-0.070556",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress",
      "url": "https://www.globenewswire.com/news-release/2025/12/11/3203752/0/en/Immatics-Presents-IMA203CD8-PRAME-Cell-Therapy-Data-from-Ongoing-Dose-Escalation-and-Shows-Promising-Initial-Anti-tumor-Activity-in-PRAME-Positive-Tumors-at-ESMO-IO-2025-Congress.html",
      "time_published": "20251211T120929",
      "authors": [],
      "summary": "Immatics N.V. presented updated Phase 1a dose escalation data for its second-generation PRAME cell therapy, IMA203CD8, at the ESMO Immuno-Oncology Congress 2025. The data showed promising initial anti-tumor activity and manageable tolerability in heavily pre-treated patients with various PRAME-positive solid tumors, including deep and durable responses. Immatics aims to position IMA203CD8 for tumor-agnostic treatment of advanced PRAME cancers beyond melanoma, starting with gynecologic cancers.",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/754fba1f-531a-483b-a574-a027f4add35e/image1.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.934684"
        }
      ],
      "overall_sentiment_score": 0.416626,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.410486",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Immatics (IMTX) posts early IMA203CD8 PRAME trial data with deep responses",
      "url": "https://www.stocktitan.net/sec-filings/IMTX/6-k-immatics-n-v-current-report-foreign-issuer-8f15bdafc90f.html",
      "time_published": "20251210T071004",
      "authors": [],
      "summary": "Immatics (IMTX) reported encouraging early Phase 1a clinical trial data for its IMA203CD8 PRAME-targeted cell therapy, showing deep and durable responses in heavily pre-treated patients with advanced solid tumors. The data, cut off on October 27, 2025, included three complete responses and two confirmed partial responses, with a manageable safety profile. Immatics plans to continue development for PRAME-positive cancers beyond melanoma and expects to determine a recommended Phase 2 dose in 2026.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.918411"
        }
      ],
      "overall_sentiment_score": 0.891582,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.896930",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Immatics Completes $116.5 Million Share Offering to Boost R&D",
      "url": "https://www.tipranks.com/news/company-announcements/immatics-completes-116-5-million-share-offering-to-boost-rd",
      "time_published": "20251209T000921",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Immatics (IMTX) has completed a share offering, successfully raising $116.5 million. These funds are earmarked for bolstering the company's research and development pipeline, manufacturing capabilities, and potential commercialization of its product candidates to strengthen its biopharmaceutical market position. Spark, TipRanks\u2019 AI Analyst, currently rates IMTX as Neutral, citing financial performance challenges alongside positive technical indicators.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2051377127-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.861190"
        },
        {
          "topic": "finance",
          "relevance_score": "0.743357"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.953255"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.766771"
        }
      ],
      "overall_sentiment_score": 0.333883,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.301738",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "How Investors Are Reacting To Immatics (IMTX) $125 Million Follow-On Equity Offering",
      "url": "https://www.sahmcapital.com/news/content/how-investors-are-reacting-to-immatics-imtx-125-million-follow-on-equity-offering-2025-12-07",
      "time_published": "20251207T100832",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Immatics N.V. (IMTX) recently announced a follow-on equity offering to raise approximately $125 million by issuing 12,500,000 ordinary shares at $10.00 each. This capital raise, while extending their cash runway and potentially easing near-term financing risks, dilutes existing shareholders and emphasizes execution risk for their T-cell therapies. Investors are now focused on how the company will utilize this funding to achieve future clinical and partnership milestones and validate its current valuation.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.946441"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.808969"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.923866"
        },
        {
          "topic": "finance",
          "relevance_score": "0.722420"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.613402"
        }
      ],
      "overall_sentiment_score": -0.277031,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.972186",
          "ticker_sentiment_score": "-0.284085",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "How Investors Are Reacting To Immatics (IMTX) $125 Million Follow-On Equity Offering",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imtx/immatics/news/how-investors-are-reacting-to-immatics-imtx-125-million-foll/amp",
      "time_published": "20251207T041302",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Immatics N.V. recently announced a follow-on equity offering of 12.5 million shares at US$10.00 each, aiming to raise US$125 million, which is expected to close on December 8, 2025. This capital raise significantly extends the company's cash runway, easing near-term financing risks but also diluting existing shareholders and increasing execution expectations. While some in the Simply Wall St Community see a wide range of fair value estimates for IMTX, the offering highlights the ongoing challenge of financing for clinical-stage biopharmaceutical companies with significant ongoing losses.",
      "banner_image": "NULL",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.949126"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.822743"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.816992"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.931339"
        },
        {
          "topic": "finance",
          "relevance_score": "0.741666"
        }
      ],
      "overall_sentiment_score": -0.21425,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.241654",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Immatics Announces $125 Million Underwritten Offering",
      "url": "https://www.tradingview.com/news/reuters.com,2025:newsml_TUA4KM9P6:0-immatics-announces-125-million-underwritten-offering/",
      "time_published": "20251206T110940",
      "authors": [
        "Reuters"
      ],
      "summary": "Immatics (IMTX) announced a $125 million underwritten offering. The company plans to sell 12,500,000 ordinary shares at $10.00 per share.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.834622"
        }
      ],
      "overall_sentiment_score": 0.026419,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.337459",
          "ticker_sentiment_score": "0.007059",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28%",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imtx/immatics/news/revenues-not-telling-the-story-for-immatics-nv-nasdaqimtx-af",
      "time_published": "20251206T041302",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Despite a recent 28% surge in its share price over the past month, Immatics N.V. (NASDAQ:IMTX) faces scrutiny due to its high price-to-sales (P/S) ratio of 14.6x, significantly above the biotech industry average. The company's revenue has declined by 27% last year and 44% over three years, while analyst forecasts project an 8.4% annual revenue growth for Immatics, starkly contrasting the industry's expected 128% growth. This disparity suggests that the market may be overly bullish on Immatics, potentially setting up investors for disappointment if the P/S ratio adjusts to align with its weaker growth outlook.",
      "banner_image": "https://images.simplywall.st/asset/chart/8986547-ps-multiple-vs-industry-1-dark-2/1764929219576",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.923723"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.845870"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.707059"
        }
      ],
      "overall_sentiment_score": 0.025829,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.311977",
          "ticker_sentiment_score": "0.033522",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics (NASDAQ: IMTX) to sell 12,500,000 shares at $10.00 in underwritten offering",
      "url": "https://www.stocktitan.net/news/IMTX/immatics-announces-125-million-underwritten-ofertwgjs8wk.html",
      "time_published": "20251206T041302",
      "authors": [
        "NULL"
      ],
      "summary": "Immatics (NASDAQ: IMTX) announced an underwritten offering to sell 12,500,000 ordinary shares at $10.00 per share, aiming to generate $125 million in gross proceeds. The offering is expected to close on December 8, 2025, with Jefferies, Leerink Partners, and Cantor acting as joint book-running managers. A registration statement for the securities was declared effective on April 3, 2025.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "0.911647"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.834123"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.700950"
        }
      ],
      "overall_sentiment_score": 0.045767,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.216184",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.603800",
          "ticker_sentiment_score": "0.108012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.633275",
          "ticker_sentiment_score": "0.121982",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.608665",
          "ticker_sentiment_score": "0.107737",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.625671",
          "ticker_sentiment_score": "0.141377",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics N.V.'s (NASDAQ:IMTX) 28% Price Boost Is Out Of Tune With Revenues",
      "url": "https://news.futunn.com/en/post/65848438/immatics-nv-s-nasdaq-imtx-28-price-boost-is-out",
      "time_published": "20251205T180700",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Immatics N.V. (NASDAQ:IMTX) has seen a significant 28% increase in its share price over the last month, contributing to a 55% gain over the past year. However, its current price-to-sales (P/S) ratio of 14.6x is elevated compared to the biotech industry average, particularly considering the company's revenue decline of 27% over the last year. Analysts forecast an 8.4% annual revenue increase for Immatics, which is significantly lower than the projected 128% annual growth for the broader industry, suggesting its high P/S ratio may be unsustainable.",
      "banner_image": "https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20251205/0-1760c22cd7cfbac7378de95f89390272-0-a39e528d1a259205659b29a35dcd6149.png/big",
      "source": "\u5bcc\u9014\u725b\u725b",
      "category_within_source": "General",
      "source_domain": "\u5bcc\u9014\u725b\u725b",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.902622"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.833399"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.715200"
        }
      ],
      "overall_sentiment_score": -0.641605,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.629107",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Immatics Announces $125 Million Underwritten Offering",
      "url": "https://www.globenewswire.com/news-release/2025/12/05/3200531/0/en/Immatics-Announces-125-Million-Underwritten-Offering.html",
      "time_published": "20251205T060000",
      "authors": [
        "NULL"
      ],
      "summary": "Immatics N.V. announced an underwritten offering to sell 12,500,000 ordinary shares at $10.00 per share, aiming to raise $125 million gross proceeds. The offering is expected to close on December 8, 2025, pending customary closing conditions. Jefferies, Leerink Partners, and Cantor are serving as joint book-running managers.",
      "banner_image": "https://ml-eu.globenewswire.com/media/Njc2ZmVmOTMtNzZjOS00N2Q2LThjZTUtMTJmOTM0NDExZjdiLTEyMDc2MjQtMjAyNS0xMi0wNS1lbg==/tiny/Immatics-N-V-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.941548"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.846018"
        }
      ],
      "overall_sentiment_score": -0.266093,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.258100",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering",
      "url": "https://www.quiverquant.com/news/Immatics+N.V.+Announces+Agreement+to+Sell+12.5+Million+Ordinary+Shares+in+Underwritten+Offering",
      "time_published": "20251205T041302",
      "authors": [],
      "summary": "Immatics N.V. announced an agreement to sell 12.5 million ordinary shares at $10.00 per share in an underwritten offering, aiming to raise $125 million in gross proceeds. The offering is expected to close on December 8, 2025, with Jefferies, Leerink Partners, and Cantor acting as joint book-running managers. This move strengthens the company's financial position and leadership in precision targeting of PRAME for cancer treatment.",
      "banner_image": "https://quiverquant.com/images/imtx_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.924540"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.847674"
        },
        {
          "topic": "finance",
          "relevance_score": "0.744246"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.627946"
        }
      ],
      "overall_sentiment_score": -0.099674,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.055042",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28%",
      "url": "https://www.sahmcapital.com/news/content/revenues-not-telling-the-story-for-immatics-nv-nasdaqimtx-after-shares-rise-28-2025-12-05",
      "time_published": "20251204T080905",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Immatics N.V.'s stock has seen a significant 28% rise recently, contributing to a 55% annual gain, despite its revenue having declined by 27% last year and 44% over the last three years. The company currently has a high price-to-sales (P/S) ratio of 14.6x, which is considerably higher than the industry average, even though analysts forecast its revenue growth at 8.4% annually for the next three years, compared to the industry's projected 128% growth. This discrepancy suggests investors might be overly bullish given the company's weak revenue outlook and potential future disappointment if the P/S ratio adjusts.",
      "banner_image": "https://images.simplywall.st/asset/chart/8986547-ps-multiple-vs-industry-1-dark-2/1764929219576",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.903730"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.846973"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.718758"
        }
      ],
      "overall_sentiment_score": -0.421328,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.395218",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Chardan Capital Maintains Immatics N.V. (IMTX) Buy Recommendation",
      "url": "https://www.nasdaq.com/articles/chardan-capital-maintains-immatics-nv-imtx-buy-recommendation",
      "time_published": "20251124T070400",
      "authors": [
        "George Maybach"
      ],
      "summary": "Chardan Capital has reaffirmed its Buy recommendation for Immatics N.V. (IMTX), with analysts projecting a 69.00% upside to an average one-year price target of $17.24/share. Institutional ownership remains strong, with key holders like T. Rowe Price and Baker Bros. Advisors increasing their stakes, indicating a bullish sentiment towards the company. The projected annual revenue for Immatics N.V. is 141MM, marking a 66.92% increase, while the projected annual non-GAAP EPS is -0.27.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.944282"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.833661"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.715282"
        },
        {
          "topic": "finance",
          "relevance_score": "0.607994"
        }
      ],
      "overall_sentiment_score": 0.491963,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.494050",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Immatics N.V. Reports Q3 2025 Financial Results and Progress",
      "url": "https://www.tipranks.com/news/company-announcements/immatics-n-v-reports-q3-2025-financial-results-and-progress",
      "time_published": "20251124T041302",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Immatics N.V. (IMTX) has released its Q3 2025 earnings report, detailing significant clinical advancements in its PRAME cell therapy, anzu-cel, for advanced melanoma, and expanding its TCR Bispecifics pipeline. The company reported a strong cash position of $505.8 million, ensuring operations into the second half of 2027, despite a net loss of $59.3 million due to increased R&D and reduced collaboration revenue. Immatics aims to launch anzu-cel by mid-2027 and continues to advance innovative therapies for cancer patients.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2068435553-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.938052"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.817253"
        }
      ],
      "overall_sentiment_score": 0.031622,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.303546",
          "ticker_sentiment_score": "0.011836",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics NV Misses Revenue But Keeps Analyst Fans On Board",
      "url": "https://finimize.com/content/immatics-nv-misses-revenue-but-keeps-analyst-fans-on-board",
      "time_published": "20251123T090901",
      "authors": [
        "Finimize Newsroom"
      ],
      "summary": "Immatics NV missed its third-quarter revenue targets, bringing in EUR 5.19 million, and saw its net loss widen to EUR 50.55 million due to a scrapped project with Bristol Myers Squibb. Despite this, analysts remain positive due to the company's significant cash reserves of $505.8 million and strong progress in its cell therapy pipeline, including anz-cel moving towards a 2027 launch and IMA402 entering Phase 1b trials in 2026. The market emphasizes long-term innovation milestones in the biotech sector over short-term financial fluctuations.",
      "banner_image": "https://finimize.com/_next/image?url=https%3A%2F%2Ffinimize-img.imgix.net%2Fhttps%253A%252F%252Fchivas-assets.s3-eu-west-1.amazonaws.com%252Fstatic%252Fimages%252Ftag_reuters_com_2025_newsml_L1N3WT0D7_73944768.jpeg%3Fixlib%3Dpython-3.1.2%26s%3Dd583f2e38cf0423ecfe9bf021d7996d1&w=3840&q=75",
      "source": "Finimize",
      "category_within_source": "General",
      "source_domain": "Finimize",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916640"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.821725"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.636661"
        },
        {
          "topic": "finance",
          "relevance_score": "0.635658"
        }
      ],
      "overall_sentiment_score": 0.165211,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.296818",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.632744",
          "ticker_sentiment_score": "0.014719",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics NV earnings missed by \u20ac0.04, revenue fell short of estimates",
      "url": "https://www.investing.com/news/earnings/immatics-nv-earnings-missed-by-004-revenue-fell-short-of-estimates-4363234",
      "time_published": "20251118T110922",
      "authors": [
        "Investing.com"
      ],
      "summary": "Immatics NV (NASDAQ: IMTX) reported Q3 EPS of \u20ac-0.42, missing analyst estimates by \u20ac0.04, and revenue of \u20ac5.2M, falling short of the \u20ac9.86M consensus. Despite the miss, the company's stock has seen an 81.17% increase in the last three months and 25.96% over the past year. InvestingPro rates Immatics NV's financial health as \"good performance.\"",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.913006"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.709284"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.637479"
        }
      ],
      "overall_sentiment_score": -0.407495,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.414688",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates",
      "url": "https://finance.yahoo.com/news/immatics-imtx-reports-q3-loss-131501033.html",
      "time_published": "20251117T110933",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Immatics (IMTX) reported a Q3 loss of $0.49 per share, missing the Zacks Consensus Estimate of a $0.5 loss, and saw revenues of $6.06 million, falling short of estimates by 50.71%. The company's shares have gained 43.5% year-to-date, outperforming the S&P 500. With a current Zacks Rank #3 (Hold), the stock is expected to perform in line with the market.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/zf_1wpp4e4lihErpE5wvzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNjtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2020-11/3bc15d30-250e-11eb-bffb-472fe5eb11fe",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.846081"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.724148"
        }
      ],
      "overall_sentiment_score": -0.226705,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.238338",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Prelude Therapeutics Appoints Katina Dorton, J.D., MBA To Board - citybiz",
      "url": "https://www.citybiz.co/article/760229/prelude-therapeutics-appoints-katina-dorton-j-d-mba-to-board/",
      "time_published": "20251017T123605",
      "authors": [],
      "summary": "Prelude Therapeutics has appointed Katina Dorton, J.D., MBA, to its Board of Directors, effective October 17, 2025. Ms. Dorton brings over 30 years of experience in healthcare and life sciences, including executive financial leadership and investment banking, and will succeed Mardi C. Dier as Audit Committee Chair. This appointment aims to strengthen Prelude's leadership as it advances its precision oncology drug candidates.",
      "banner_image": "https://www.citybiz.co/wp-content/uploads/2025/10/Katina-Dorton.jpg",
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.708905"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.403742"
        }
      ],
      "overall_sentiment_score": 0.027814,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.303151",
          "ticker_sentiment_score": "0.022149",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics Appoints Venkat Ramanan as Chief Financial Officer",
      "url": "https://finance.yahoo.com/news/immatics-appoints-venkat-ramanan-chief-110000404.html",
      "time_published": "20251001T110000",
      "authors": [],
      "summary": "Immatics N.V. (NASDAQ: IMTX) has appointed Venkat Ramanan, Ph.D., as its new Chief Financial Officer, effective immediately. Dr. Ramanan brings over 25 years of financial leadership experience in the biopharmaceutical industry, having previously held positions at companies including Seagen, Gilead Sciences, and Amgen. His appointment is expected to be instrumental as Immatics advances its PRAME franchise and moves its PRAME cell therapy, anzu-cel, towards commercialization.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.918422"
        },
        {
          "topic": "finance",
          "relevance_score": "0.729442"
        }
      ],
      "overall_sentiment_score": 0.319828,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.436411",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.631481",
          "ticker_sentiment_score": "0.294822",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.600336",
          "ticker_sentiment_score": "0.257603",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imtx/immatics/news/investors-dont-see-light-at-end-of-immatics-nvs-nasdaqimtx-t",
      "time_published": "20250919T000000",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Immatics N.V. (NASDAQ:IMTX) currently has a low price-to-sales (P/S) ratio of 5.2x compared to the Biotech industry average, signaling bearish sentiment among investors. This low P/S is attributed to the company's sluggish recent revenue growth and a negative forecast for future revenue, with analysts predicting a 9.1% annual decrease over the next three years while the broader industry is expected to expand significantly. The article suggests that Immatics' poor outlook justifies its current low P/S ratio and makes a strong share price increase unlikely in the near future.",
      "banner_image": null,
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.910954"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.812865"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.738312"
        }
      ],
      "overall_sentiment_score": -0.440894,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.442399",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS)",
      "url": "https://www.bizjournals.com/houston/news/2025/04/30/immatics-us-cell-therapy-plant-stafford-opens.html",
      "time_published": "20250430T000000",
      "authors": [
        "Jishnu Nair"
      ],
      "summary": "Immatics US has opened a 100,000-square-foot cell-therapy manufacturing plant in Stafford, Texas. This new facility will significantly scale up the cell-therapy process for the German drugmaker's U.S. arm. The opening was marked by a ribbon-cutting ceremony attended by Immatics executives and local elected representatives.",
      "banner_image": null,
      "source": "The Business Journals",
      "category_within_source": "General",
      "source_domain": "The Business Journals",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.940963"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.810731"
        }
      ],
      "overall_sentiment_score": 0.836679,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.843310",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Immatics Announces Full Year 2024 Financial Results and Business Update",
      "url": "https://www.globenewswire.com/news-release/2025/03/27/3050384/0/en/Immatics-Announces-Full-Year-2024-Financial-Results-and-Business-Update.html",
      "time_published": "20250327T070000",
      "authors": [],
      "summary": "Immatics N.V. announced its full year 2024 financial results and provided a business update, highlighting significant progress in its clinical-stage pipeline. The company initiated a Phase 3 trial for its lead TCR-T cell therapy, IMA203, in advanced melanoma, with cash and equivalents reaching $628.0 million, extending its reach into the second half of 2027. Immatics reported a net profit of $15.8 million for 2024, driven by collaboration revenue, reversing the previous year's net loss.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.916733"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.947885"
        }
      ],
      "overall_sentiment_score": 0.239824,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.430660",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.702798",
          "ticker_sentiment_score": "0.244118",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.633672",
          "ticker_sentiment_score": "0.139947",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics collaboration with Bristol Myers ends due to portfolio prioritization",
      "url": "https://www.tipranks.com/news/the-fly/immatics-collaboration-with-bristol-myers-ends-due-to-portfolio-prioritization",
      "time_published": "20241231T235959",
      "authors": [
        "TheFly"
      ],
      "summary": "Immatics' collaboration with Bristol Myers Squibb for the co-development of IMA401 has been terminated due to Bristol Myers Squibb's portfolio prioritization efforts. The agreement will conclude on December 12, with all development and commercialization rights for IMA401 reverting to Immatics. Immatics will retain the $150 million upfront payment and is not obligated to make future milestone payments to Bristol Myers Squibb, intending to advance IMA401 through clinical development with the next data update expected in 2025.",
      "banner_image": null,
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.914609"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.600423"
        }
      ],
      "overall_sentiment_score": 0.023899,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.310977",
          "ticker_sentiment_score": "0.008565",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics Announces Updated Phase 1b Clinical Data on ACTengine\u00ae IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial",
      "url": "https://finance.yahoo.com/news/immatics-announces-updated-phase-1b-103000214.html",
      "time_published": "20241010T103000",
      "authors": [],
      "summary": "Immatics announced updated Phase 1b clinical data for its ACTengine\u00ae IMA203 TCR-T therapy in metastatic melanoma patients, showing a confirmed objective response rate of 54% and a median duration of response of 12.1 months. The company also outlined the design for its upcoming SUPRAME Phase 3 trial, which will enroll 360 patients and use progression-free survival as the primary endpoint for full approval, with an anticipated launch in December 2024. These findings, combined with regulatory alignment with the FDA and PEI, position IMA203 for accelerated late-stage development.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.007235,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.317632",
          "ticker_sentiment_score": "0.017524",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics' cell therapy leapfrogs into phase 3 on strength of early-stage survival data",
      "url": "https://www.fiercebiotech.com/biotech/immatics-cell-therapy-leaps-phase-3-strength-early-stage-pfs-data",
      "time_published": "20241010T084900",
      "authors": [
        "Nick Paul Taylor"
      ],
      "summary": "Immatics is advancing its melanoma cell therapy, IMA203, directly into a phase 3 pivotal trial based on promising early-stage progression-free survival (PFS) data from its phase 1b study. The company aims for full approval in early 2027, leveraging PFS as the primary endpoint. To support its operations and trial, Immatics also announced a proposed $150 million public offering.",
      "banner_image": null,
      "source": "Fierce Biotech",
      "category_within_source": "General",
      "source_domain": "Fierce Biotech",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.920756"
        }
      ],
      "overall_sentiment_score": 0.174921,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.423799",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.624318",
          "ticker_sentiment_score": "-0.117740",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immatics Announces Pricing of $150 Million Public Offering",
      "url": "https://finance.yahoo.com/news/immatics-announces-pricing-150-million-005000279.html",
      "time_published": "20241010T005000",
      "authors": [],
      "summary": "Immatics N.V. announced the pricing of a public offering of 16,250,000 ordinary shares at $9.25 per share, aiming to raise approximately $150 million in gross proceeds. The clinical-stage biopharmaceutical company also granted underwriters a 30-day option to purchase additional shares. The offering is expected to close on October 15, 2024, with Jefferies, BofA Securities, and Leerink Partners acting as joint book-running managers.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "0.919690"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.845788"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.717089"
        },
        {
          "topic": "finance",
          "relevance_score": "0.627015"
        }
      ],
      "overall_sentiment_score": 0.04708,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.326661",
          "ticker_sentiment_score": "0.047322",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns",
      "url": "https://finance.yahoo.com/news/heres-why-immatics-n-v-114059036.html",
      "time_published": "20240614T000000",
      "authors": [
        "editorial-team@simplywallst.com (Simply Wall St)"
      ],
      "summary": "Immatics N.V.'s CEO compensation of \u20ac6.4m in 2023 is considered reasonable and in line with industry averages, especially given the company's 49% EPS growth over the past three years. While revenue decreased, profits improved, and the CEO, Harpreet Singh, has a significant personal investment in the company. Shareholders are likely to be content with the current performance and CEO pay, which will be discussed at the upcoming AGM.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.934075"
        },
        {
          "topic": "finance",
          "relevance_score": "0.845809"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.707290"
        }
      ],
      "overall_sentiment_score": 0.256301,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.288837",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector function",
      "url": "https://onlinelibrary.wiley.com/doi/10.1002/eji.202149290",
      "time_published": "20210823T203144",
      "authors": [
        "Fabian Brunk",
        "Andreas Moritz",
        "Annika Nelde",
        "Tatjana Bilich",
        "Nicolas Casadei",
        "Sabine A. K. Fraschka",
        "Jonas S. Heitmann",
        "Sebastian H\u00f6rber",
        "Andreas Peter",
        "Hans-Georg Rammensee",
        "Harpreet Singh",
        "Juliane Walz",
        "Dominik Maurer",
        "Claudia Wagner"
      ],
      "summary": "This research article identifies and characterizes SARS-CoV-2-reactive T-cell receptors (TCRs) isolated from convalescent COVID-19 patients. The study demonstrates that these TCRs are highly functional, mediating potent T-cell effector functions including robust IFN-\u03b3 responses and in vitro cytotoxicity, comparable to a high-affinity control TCR. The findings contribute to understanding anti-SARS-CoV-2 T-cell immunity and suggest potential for immunotherapeutic approaches.",
      "banner_image": null,
      "source": "Wiley Online Library",
      "category_within_source": "General",
      "source_domain": "Wiley Online Library",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925027"
        }
      ],
      "overall_sentiment_score": 0.441136,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.400875",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ogier Advises On $253,000,000 ARYA Sciences Acquisition Corp Business Combination With Immatics Biotechnologies GmbH",
      "url": "https://www.mondaq.com/jersey/shareholders/968110/ogier-advises-on-%24253000000-arya-sciences-acquisition-corp-business-combination-with-immatics-biotechnologies-gmbh",
      "time_published": "20200721T223224",
      "authors": [
        "Angus Davison",
        "Michael Robinson"
      ],
      "summary": "Ogier's Cayman Islands team advised ARYA Sciences Acquisition Corp (ARYA) on its $253 million business combination with Immatics Biotechnologies GmbH. The transaction, which resulted in Immatics N.V. trading on the Nasdaq Capital Market, saw no redemptions from ARYA's shareholders. Partner Angus Davison and senior associate Michael Robinson led the Ogier team for this significant deal.",
      "banner_image": null,
      "source": "Mondaq",
      "category_within_source": "General",
      "source_domain": "Mondaq",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.838416"
        },
        {
          "topic": "finance",
          "relevance_score": "0.748002"
        }
      ],
      "overall_sentiment_score": 0.039698,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMTX",
          "relevance_score": "0.349381",
          "ticker_sentiment_score": "0.021120",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}